ArticleVaccine2025
Associated factors for dropout of first versus third doses of pentavalent vaccination in Tanzania.
Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The pentavalent is a vaccine against Diphtheria, Pertussis, Tetanus, Hepatitis B, and Haemophilus type B influenza. A child is considered a pentavalent vaccination dropout if they have received the first dosage as advised but have not obtained the third dose. In Tanzania, the first-dose receiver of pentavalent was approximately 97 %, whereas only 89 % received a third dose. Unfortunately, no studies have been done in Tanzania to evaluate the factors at the national level that are linked with first-versus third-dose pentavalent vaccine dropout; hence, we explored these factors here for the first time. A cross-sectional survey of randomly selected households was conducted. The sample size was calculated to provide overall, age- and sex-specific coverage estimates for measles-rubella vaccine evaluation among children aged between 9 and 59 months at the national level, as explained elsewhere. The fieldwork activities were done for one month from November to December 2019 for both Zanzibar and Tanzania Mainland. A total of 4460 caregivers of children aged 12-23 months were interviewed for routine immunization services, and a total of 4403 caregivers were included in this analysis of the uptake of the pentavalent vaccine. The number of children who received the first dose of the pentavalent vaccine was 4020 (91.5 %), while the number of children who received the third dose of the pentavalent vaccine was 3915 (89.4 %). The overall pentavalent vaccination dropout rate was 2.3 %. The rate was lower in Zanzibar (0.9 %) than in the Tanzanian mainland (2.4 %). Wealth quintile, sex of caregivers, and education were factors significantly associated with the pentavalent-3 dropout rate among children aged 12-23 months in Tanzania. Our results provide strong support for further efforts to improve current vaccination coverage to optimize the use of prioritized, timely, and appropriate interventions at the regional and district levels and to improve the health education given to expectant women during their clinic visits so they may comprehend the value of routine immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.